# Everolimus Therapy in People With Birt-Hogg-Dube Syndrome (BHD)-Associated Kidney Cancer or Sporadic Chromophobe Renal Cancer

> **NCT02504892** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 3 (actual)

## Conditions studied

- Renal Cancer
- Birt-Hogg-Dube Syndrome

## Interventions

- **DRUG:** Everolimus

## Key facts

- **NCT ID:** NCT02504892
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-07-21
- **Primary completion:** 2018-04-17
- **Final completion:** 2018-04-17
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Study was terminated due to slow, insufficient accrual.
- **Last updated:** 2019-03-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02504892

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02504892, "Everolimus Therapy in People With Birt-Hogg-Dube Syndrome (BHD)-Associated Kidney Cancer or Sporadic Chromophobe Renal Cancer". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT02504892. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*